<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05056584</url>
  </required_header>
  <id_info>
    <org_study_id>H-16043802</org_study_id>
    <nct_id>NCT05056584</nct_id>
  </id_info>
  <brief_title>The Role of the Kidneys and Liver in the Elimination of Glucagon</brief_title>
  <acronym>MCR_EndCir</acronym>
  <official_title>The Role of the Kidneys and Liver in the Elimination of Glucagon An Evaluation of the Metabolic Clearance Rate of Glucagon in Patients With End-stage Renal Disease and Patients With Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Novo Nordisk Foundation Center for Basic Metabolic Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the kinetics and effect of glucagon in patients with End-stage&#xD;
      Renal Disease and liver cirrhosis and matched healthy subjects, respectively.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the present project the investigators wish to identify whether the effect, elimination and&#xD;
      degradation of glucagon differ between healthy control subjects and patients with End-stage&#xD;
      Renal Disease (ESRD) and liver cirrhosis, respectively. By performing glucagon infusions on&#xD;
      healthy control subjects and matched subjects with either limited renal and hepatic function,&#xD;
      the contribution of both organs to the metabolic clearance rate (MCR) of glucagon can be&#xD;
      tested. A primed infusion of stable isotopic labelled tracers will allow the researchers to&#xD;
      investigate the effects of the glucagon infusion on the glucose, lipid and amino acid&#xD;
      metabolism.&#xD;
&#xD;
      The quantification of the MCR of glucagon will be accompanied by a range of pharmacodynamic&#xD;
      measures in order to substantiate whether a potentially altered glucagon MCR inflicts&#xD;
      pharmacodynamic changes of glucagon, which could contribute to the pathophysiology of ESRD&#xD;
      and liver cirrhosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic clearance rate of glucagon</measure>
    <time_frame>t = 50 minutes</time_frame>
    <description>Glucagon plasma concentration steady state glucagon concentrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucagon pharmacokinetic 1</measure>
    <time_frame>-120, -90, -60, -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes</time_frame>
    <description>Elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon pharmacokinetic 2</measure>
    <time_frame>-120, -90, -60, -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes</time_frame>
    <description>volume of distribution of Glucagon</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon pharmacodynamic - amino acids</measure>
    <time_frame>-120, -90, -60, -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes</time_frame>
    <description>Effect of glucagon on amino acid plasma levels before, during and after infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon pharmacodynamic - glucose</measure>
    <time_frame>-120, -90, -60, -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes</time_frame>
    <description>Effect of glucagon on plasma glucose levels before, during and after infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tracers</measure>
    <time_frame>-120, -90, -60, -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120</time_frame>
    <description>Tracer-to-tracee ratio of labelled isotopes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>-120, -90, -60, -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes</time_frame>
    <description>Excursions of plasma concentrations of insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon-like peptide 1</measure>
    <time_frame>-120, -90, -60, -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes</time_frame>
    <description>Excursions of plasma concentrations of GLP-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism</measure>
    <time_frame>-120, -90, -60, -30, -15, 0, 5, 10, 20, 50, 55, 60, 62, 64, 66, 68, 70, 75, 80, 85, 90, 120 minutes</time_frame>
    <description>Effect of glucagon on lipid metabolism, through lipidomics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital parameter 1</measure>
    <time_frame>-120, -30, 0, 60, 120 minutes</time_frame>
    <description>Systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital parameter 2</measure>
    <time_frame>-120, -30, 0, 60, 120 minutes</time_frame>
    <description>Diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital parameter 3</measure>
    <time_frame>-120, -30, 0, 60, 120 minutes</time_frame>
    <description>Heart rate</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>End-stage Renal Disease</condition>
  <condition>Liver Cirrhosis</condition>
  <condition>Hyperglucagonemia</condition>
  <arm_group>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy control subjects, matched for age, sex and BMI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with End-stage Renal Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with hemodialysis-treated ESRD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with liver cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Child-Pugh A or B Cirrhosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Glucagon infusion</intervention_name>
    <description>One hour glucagon-clamp followed by one hour of blood sampling</description>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <arm_group_label>Patients with End-stage Renal Disease</arm_group_label>
    <arm_group_label>Patients with liver cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Primed tracer infusion</intervention_name>
    <description>Infusion of primed isotopically labelled glucose, amino acids and lipids. From 2 hours prior to glucagon infusion and throughout the test day,</description>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <arm_group_label>Patients with End-stage Renal Disease</arm_group_label>
    <arm_group_label>Patients with liver cirrhosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The ESRD group&#xD;
&#xD;
          -  Men/women between 18 and 75 years of age&#xD;
&#xD;
          -  Chronic haemodialysis-treated ESRD for at least 3 months&#xD;
&#xD;
          -  Dialysis access via a fistula or a permanent catheter&#xD;
&#xD;
          -  Normal liver function (alanine aminotransferase (ALAT), aspartate aminotransferase&#xD;
             (ASAT), albumin and coagulation factor II, VII and X (INR) within normal range,&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        The cirrhosis group&#xD;
&#xD;
          -  Men/women between 18 and 75 years of age&#xD;
&#xD;
          -  Verified diagnosis of cirrhosis - Child-Pugh Score of 5-12&#xD;
&#xD;
          -  Normal kidney function (estimated glomerular filtration rate (eGFR) above 60&#xD;
             ml/min/1.73m2 and absence of proteinuria)&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        The control group&#xD;
&#xD;
          -  Men/women between 18 and 75 years of age&#xD;
&#xD;
          -  Normal kidney function (estimated glomerular filtration rate (eGFR) above 60&#xD;
             ml/min/1.73m2 and absence of proteinuria)(plasma creatinine ≤105 micromol/L (µM) for&#xD;
             men and ≤90 µM for women)&#xD;
&#xD;
          -  Normal liver function (alanine aminotransferase (ALAT), aspartate aminotransferase&#xD;
             (ASAT), albumin and coagulation factor II, VII and X (INR) within normal range&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All groups&#xD;
&#xD;
          -  Diagnosis of diabetes and/or HbA1c ≥43 mmol/mol and/or fasting plasma glucose ≥6&#xD;
             mmol/l.&#xD;
&#xD;
          -  Previous kidney transplantation with remaining kidney graft&#xD;
&#xD;
          -  Present treatment with oral glucocorticoids&#xD;
&#xD;
          -  Polycystic kidney disease&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Surgical procedure within the last 3 months&#xD;
&#xD;
          -  Haemoglobin &lt; 6 mmol/l (women) or &lt; 7 mmol/l (men)&#xD;
&#xD;
          -  First-degree relatives with diabetes&#xD;
&#xD;
          -  Any condition that the investigators feel would interfere with trial participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip K Knop, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Center for Metabolic Research, Gentofte Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magnus FG Grøndahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Metabolic Research, Gentofte Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magnus FG Grøndahl, MD</last_name>
    <phone>29362445</phone>
    <email>magnus.frederik.gluud.groendahl@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Filip K Knop, MD, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Clinical Metabolic Research, Department of Medicine, Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <state>Copenhagen</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus FG Grøndahl, MD</last_name>
      <email>Magnusgroendahl@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Filip Knop, MD, PhD</last_name>
      <email>filipknop@dadlnet.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Filip K Knop, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magnus FG Grøndahl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2021</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Magnus Frederik Gluud Grøndahl</investigator_full_name>
    <investigator_title>Principal investigator, Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Metabolic clearance rate</keyword>
  <keyword>Glucagon pharmacodynamics</keyword>
  <keyword>Glucagon pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

